

Ref: FOI/GS/ID 7880

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

02 August 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Local Treatment Guidelines Non-Small Cell Lung Cancer.

You asked:

Question 1

Does Maidstone and Tunbridge Wells NHS Trust have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?

Question 2

Does Maidstone and Tunbridge Wells NHS Trust have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?

- a. *Sotorasib (Lumykras)*
- b. *Entrectinib (Rozlytrek)*
- c. *Larotrectinib (Vitrakvi)*
- d. *Dabrafenib (Tafinlar)*
- e. *Trametinib (Mekinist)*
- f. *Capmatinib (Tabrecta)*
- g. *Tepotinib (Tepmetko)*
- h. *Bevacizumab (Avastin)*
- i. *Ramucirumab (Cyramza)*
- j. *Atezolizumab (Tecentriq)*
- k. *Durvalumab (Imfinzi)*
- l. *Cemiplimab- (Libtayo)*
- m. *Nivolumab (Opdivo)*
- n. *Pembrolizumab (Keytruda)*
- o. *Ipilimumab (Yervoy)*
- p. *Afatinib (Giotrif)*
- q. *Dacomitinib (Vizimpro)*

- r. Erlotinib (Tarceva)
- s. Gefitinib (Iressa)
- t. Osimertinib (Tagrisso)
- u. Amivantamab (Rybrevant)
- v. Mobocertinib (Exkivity)
- w. trastuzumab deruxtecan (Enhertu)
- x. Alectinib (Alecensa)
- y. Brigatinib (Alunbrig)
- z. Ceritinib (Zykadia)
- aa. Crizotinib (Xalkori)
- bb. Lorlatinib (Lorviqua)
- cc. Entrectinib (Rozlytrek)
- dd. Pralsetinib (Gavreto)
- ee. Selpercatinib (Retsevmo)
- ff. Nintedanib (Vargatef®)

Question 3

If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?

Question 4

Does Maidstone and Tunbridge Wells NHS Trust have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?

Question 5

Is Maidstone and Tunbridge Wells NHS Trust part of a Cancer alliance or network, if so which ones?

Trust response:

1. The treatment guidelines and protocols for NSCLC are available to download on the KMCC website:

[Kent and Medway Cancer Collaborative - Medicines and Prescribing \(incorporating SACT Pathways\) \(kmcc.nhs.uk\)](https://www.kmcc.nhs.uk/medicines-and-prescribing)

2.

Sotorasib (Lumykras)	Yes	
	<i>If yes please see question 3</i>	
Entrectinib (Rozlytrek)	Yes	
Larotrectinib (Vitrakvi)	Yes	
Dabrafenib (Tafinlar)	Yes	
Trametinib (Mekinist)	Yes	
Capmatinib (Tabrecta)		No
Tepotinib (Tepmetko)	Yes	
Bevacizumab (Avastin)	Yes	
Ramucirumab (Cyramza)		No
Atezolizumab (Tecentriq)	Yes	
Durvalumab (Imfinzi)	Yes	
Cemiplimab- (Libtayo)		No
Nivolumab (Opdivo)	Yes	
Pembrolizumab (Keytruda)	Yes	

Ipilimumab (Yervoy)		No
Afatinib (Giotrif)	Yes	
Dacomitinib (Vizimpro)	Yes	
Erlotinib (Tarceva)	Yes	
Gefitinib (Iressa)	Yes	
Osimertinib (Tagrisso)	Yes	
Amivantamab (Rybrevant)		No
Mobocertinib (Exkivity)	Yes	
trastuzumab deruxtecan (Enhertu)		No
Alectinib (Alecensa)	Yes	
Brigatinib (Alunbrig)	Yes	
Ceritinib (Zykadia)	Yes	
Crizotinib (Xalkori)	Yes	
Lorlatinib (Lorviqua)	Yes	
Entrectinib (Rozlytrek)	Yes	
Pralsetinib (Gavreto)		No
Selpercatinib (Retsevmo)	Yes	
Nintedanib (Vargatef®)	Yes	

3. The protocol is attached to this email.
4. Unable to source this information.
5. Kent and Medway Cancer Alliance and have TSSG meeting's quarterly.